DYSPEPSIA MANAGEMENT

Natural history of dyspepsia

L Agréus

Many individuals in the Western world suffer from heartburn, acid regurgitation, abdominal pain, or bowel habit disturbances. The reported prevalence of dyspepsia is approximately 25% with similar values for gastro-oesophageal reflux disease. While prevalence rates are stable over time, substantial changes occur in the main symptom profiles of sufferers. The economic costs of dyspepsia are considerable.

SUMMARY

A new definition of dyspepsia has been proposed: pain or discomfort centred in the upper abdomen. Here, discomfort refers to a subjective negative feeling but one that the patient does not interpret as pain. Duration is not specified. Concomitant predominant reflux symptoms are separated out as gastro-oesophageal reflux disease (GORD). Irritable bowel syndrome (IBS) pain is also an exclusion criterion if epigastric pain is related to bowel habit disturbances. If not, IBS and dyspepsia can present concomitantly. Reported prevalences of dyspepsia vary considerably, with the average reported value being approximately 25%. Similar values are reported for GORD. The simultaneous occurrence of reflux, dyspeptic, and IBS symptoms is common. Prevalence rates are stable over time but substantial changes occur in the main symptom profiles of sufferers. Those reporting predominant reflux have fluctuating symptom intensity but rarely change their main symptom profile to dyspepsia or IBS. The two latter disorders also change in intensity over time but sufferers often change their main symptom profile between the two diagnoses, although not to predominant reflux. Psychosocial factors such as neuroticism, mood disorders, and quality of life have been found to contribute to the morbidity associated with dyspepsia. The economic costs of dyspepsia are hard to compare between countries because of differences in sickness benefits and drug prescription rules and subsidies. In Sweden, the overall cost seems to have decreased substantially over the past decade, mostly because of a decrease in the cost of short term sick leave arising from impaired sickness benefits, while the cost of drugs has increased.

INTRODUCTION

Many individuals in the Western world are troubled by heartburn, acid regurgitation, abdominal pain, or bowel habit disturbances; up to one in two subjects in cross sectional population based studies report such symptoms. The reported prevalence of symptomatic GORD has ranged, on average, from 15% to 25%, while for dyspepsia the reported prevalence range in populations is 15–40%. One reason for the wide ranges reported is that there have been no overall agreed definitions of the disorders.

DEFINITION OF DYSPESIA

For a long time, dyspepsia had no generally agreed definition, causing difficulties for both clinicians and researchers. Then, in the late 1980s, an international working group, assembled in Chicago, recommended that dyspepsia be defined broadly as any epigastric or retrosternal symptom of supposed gastrointestinal origin lasting for more than four weeks. It was also suggested that symptoms be pooled into four subgroups to reflect their most likely underlying pathophysiology, and therefore guide clinicians in their choice of therapy. The subgroups were labelled reflux-like, ulcer-like, dysmotility-like, and unspecified (non-specific) dyspepsia. The set of symptoms for each of these subgroups is presented in table 1. With this definition of dyspepsia, all individuals reporting symptoms of GORD were included, and concomitant IBS was not considered an exclusion criterion.

In 1991, the Rome working party proposed that dyspeptic patients with predominant reflux symptoms (heartburn and acid regurgitation) should be considered as having GORD until proved otherwise because the majority of these patients will have an organic cause for their symptoms (that is, macroscopic or histological oesophagitis). In addition, those presenting with concomitant IBS symptoms should be diagnosed as having IBS and not dyspepsia. Dyspepsia was defined more clearly and simply as pain or discomfort in the upper abdomen. Chronic dyspepsia was defined as dyspeptic symptoms present for at least 25% of the time for at least one month. Functional (non-ulcer) dyspepsia was defined as chronic dyspepsia in the absence of a definite structural disease. Only ulcer-like, dysmotility-like, and unspecified dyspepsia were considered as subgroups. The 1991 Rome definition is now widely accepted although still under debate. The terms pain and discomfort may be interpreted differently in different countries and cultures and the definition may not cover all of the possible linguistic aspects of dyspepsia. A new working team has therefore proposed an updated definition, referred to as the Rome II definition. This
still defines dyspepsia as pain or discomfort centred in the upper abdomen but further clarification has been added. “Centred” refers to symptoms mainly in or around the midline. Whether or not discomfort represents part of the spectrum of pain is discussed, and the term discomfort is taken to refer to a subjective negative feeling but one that the patient does not interpret as pain (in all languages and cultures) and which, if fully assessed, can include a number of specific symptoms. Discomfort may be characterised by, or associated with, upper abdominal fullness, early satiety, bloating, belching, or nausea. These symptoms are typically accompanied by a component of upper abdominal distress. Duration is not specified as part of the definition. Concomitant predominant reflux symptoms are separated out as GORD and not called dyspepsia. IBS pain is also an exclusion criterion if not, IBS and dyspepsia can present concomitantly.

The dyspepsia subgroups shown in table 1 have been questioned because there does not appear to be a clinically useful connection between the symptom subgroups and pathophysiology. The prevalence of peptic ulcers is approximately the same in all symptom clusters, and dysmotility and unspecified hypersensitivity do not differ in a clinically useful way. Hence the groups do not guide the clinician, as originally intended, when choosing between prokinetic and acid reducing drugs for patients with uninvestigated dyspepsia. The Rome II working team emphasises this and proposes that “the predominant or most bothersome symptom” should be identified as a working hypothesis for future research to test. The dyspepsia subgroups based on this concept are shown in table 2.

### Table 1: Dyspepsia subgroups and symptom profiles according to former definitions

- **Reflux-like dyspepsia**
  - Heartburn
  - Acid regurgitation
- **Ulcer-like dyspepsia**
  - Three or more of the following symptoms, but upper abdominal pain must be predominant
    - Epigastric pain
    - Pain relieved by food
    - Pain relieved by antacids or acid reducing drugs
    - Pain occuring before meals or when hungry
    - Pain that at times wakes the patient from sleep
    - Periodic pain with remission and relapses
- **Dysmotility-like dyspepsia**
  - An unpleasant or troublesome non-painful sensation (discomfort) centred in the upper abdomen is the predominant symptom; this sensation may be characterised by or associated with upper abdominal fullness, early satiety, bloating, belching, or nausea
- **Unspecified dyspepsia**
  - Dyspeptic symptoms that cannot be classified into the above three symptom profiles

### Table 2: Dyspepsia subgroups based on the predominant or most bothersome symptoms, according to the Rome II working team

- **Ulcer-like dyspepsia**
  - Pain centred in the upper abdomen is the predominant (most bothersome) symptom
- **Dysmotility-like dyspepsia**
  - An unpleasant or troublesome non-painful sensation (discomfort) centred in the upper abdomen is the predominant symptom; this sensation may be characterised by or associated with upper abdominal fullness, early satiety, bloating, belching, or nausea
- **Unspecified dyspepsia**
  - Cannot be classified as above

### Prevalence of Dyspepsia and GORD

**Dyspepsia**

The reported prevalence of dyspepsia varies considerably, to some extent depending on the various definitions used and also on the period of time patients are under surveillance. Values of between 7% and 63% have been reported, with a mean of approximately 25%. The overall findings from studies of different populations are given below, in chronological order.

In England in 1951, Doll and Jones reported dyspeptic symptoms in 32% of males and 30% of females during the five years preceding their investigation, with worse symptoms occurring in males. Weir and Backett in 1968 reported a 23% prevalence rate for dyspepsia over a three month period in Scottish males, with 29% having had dyspepsia at some point in their life. In this study, the proportion of more harmless symptoms decreased with age. In a Swedish investigation published by Johansson in 1970, 21% of individuals had suffered abdominal pain over the previous year and, of these, one in four reported severe pain; the prevalence was about the same in both sexes, decreasing with age mainly among those reporting mild symptoms. Banke in 1975 found that 26% of the Danish population reported dyspepsia, with a maximum value of 34% in younger (25–35 years) males and 32% in older (35–65 years) females.

In the 1980s, in a Swedish survey, Tibblin et al reported a decrease with age in almost all of the abdominal symptoms investigated, the decrease being most marked in females; the prevalence of dyspepsia over three months was about 26% in 50 year olds but abdominal pain was reported by 39% of younger females. In 1982, Hollnagel et al reported that 25% of the 40 year old Danish population had suffered epigastric
pain during the year preceding the survey, and that 31% had experienced such pain at some point in their life. In a Norwegian total population survey in 1988, Johnsen et al found the lifetime prevalence of non-ulcer dyspepsia to be 23% among males and 18% among females—the prevalence increased significantly with age in both sexes, as did reflux symptoms. In a Peruvian urban population studied by Barros and Pamo in 1989, 54% were found to have dyspepsia.

In two studies published by Jones and Lydeard in 1989 and 1990, the six month prevalence of dyspeptic symptoms was 38% and 41%; there was no difference between males and females except for a decrease with age that was significant only in males, and the lifetime prevalence was 63%. Also in 1990, Bernersen et al reported that 27% of their Norwegian study population had suffered from epigastric pain and/or heartburn at some point. In a random community based survey in rural northeastern Nigeria in 1991, Holcombe et al reported a 26% prevalence of dyspepsia over six months which increased with age. However, in a previous study from the same country, the prevalence was 45% for the same time span. Schlemper et al in 1993 found a prevalence of non-ulcer dyspepsia of 13% in both the Netherlands and Japan in working populations; the prevalence was twice as high among females in both countries. In 1997, in a preliminary report from Hong Kong, Hu et al found a prevalence of 19% in a Chinese population. Holtmann et al reported a 21% prevalence of dyspepsia over one year in a German randomly selected population.

In southern Europe the reports are sparse. Cupella et al reported that 61% of a small sample of workers (n=102) in Italy had dyspepsia although it is doubtful whether this result can be extrapolated to the general population. In France, for example, Bommelaer et al reported abdominal pain in 14% of a random population; however, 14% seems low compared with other studies on overall abdominal pain—in a Swedish study by Agréus et al, the three month prevalence of having any troublesome abdominal pain was 36%, and in a study by Welch and Pomare in New Zealand, values were 26% for males and 32% for females.

In Olmsted County, Minnesota, USA, Talley et al reported a one year overall prevalence of dyspepsia of 26%, with 16% of these having ulcer-like dyspepsia. In Australia, a prevalence of dyspepsia of 12% has been reported by Talley et al for a 12 month period. In the Swedish study cited above, the overall prevalence of dyspepsia in the unselected population was 32.2% for a three month period. If those patients with only reflux symptoms (“predominant reflux”) were excluded, 24.8% were defined as having dyspepsia, and 13.9% if those with concomitant bowel habit disturbances (that is, IBS) were also excluded (fig 1).

**GORD**

As with dyspepsia, the definitions of GORD used in different investigations are divergent. However, when attempting to identify individuals suffering from heartburn or acid regurgitation, approximately 25% of the population seems to report reflux symptoms, and about one third of these “predominant reflux symptoms”. Again, the main conclusions from such studies are given below in chronological order.

In a non-randomly selected US population, Nebel et al in 1976 reported prevalences of 7% for daily heartburn and 36% for monthly heartburn among responders, with no significant trend for age. Kjellén and Tibbling in 1981 found acid regurgitation or heartburn in 16%, dysphagia in 15%, globus sensations in 12%, and “chest oppression sensation” in 23% of a

---

**Table 3** The three month incidence (number per 100) in a Swedish population based study of predominant reflux symptoms (no concomitant abdominal pain; “reflux”), dyspepsia (only reflux and irritible bowel syndrome (IBS) excluded) and IBS.

<table>
<thead>
<tr>
<th>Incidence (%)</th>
<th>% 95% CI % 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reflux</td>
<td>0.05 0.00–0.25</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>0.8 0.0–1.6</td>
</tr>
<tr>
<td>IBS</td>
<td>0.2 0.0–0.6</td>
</tr>
</tbody>
</table>

*Denotes newly occurring disease among those who were previously symptom free and those who had other symptoms/symptom clusters previously (but not the cluster under consideration)
Based on one year occurrence.
CI, confidence interval.

---

**Table 4** Symptom overlap in dyspepsia and irritible bowel syndrome (IBS) in patient and population based studies.

<table>
<thead>
<tr>
<th>Percentage of individuals with IBS reporting concomitant dyspepsia</th>
<th>Dotevall et al 12</th>
<th>87%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Talley et al 46</td>
<td>29%</td>
<td></td>
</tr>
<tr>
<td>Jones and Lydeard 45</td>
<td>90%</td>
<td></td>
</tr>
<tr>
<td>Agréus et al 35</td>
<td>80%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Percentage of individuals with IBS reporting concomitant IBS</th>
<th>Hallnagel et al 44</th>
<th>46%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Talley and Piper 14</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>Sielaff 46</td>
<td>47%</td>
<td></td>
</tr>
</tbody>
</table>

*Population based studies.
INCIDENCE OF DYSPEPSIA AND GORD

There are only a handful of studies on the incidence (new cases) and onset (new symptoms or old symptoms that recur) of dyspepsia and reflux symptoms. Data are hard to compare because of confusion in the terminology. In Scotland, Weir and Backett reported an annual incidence of dyspepsia of 1.6% while in Denmark, Kay and Jørgensen found an annual incidence of dyspepsia of just under 25%. In an English study, Jones and Lydeard reported an annual incidence (the participants had never experienced the symptom before) of 11.5% for dyspepsia while in the USA, Talley et al reported annual onset rates (the subjects were symptomless at the first but not the second survey although they could have had symptoms in the distant past) of 5.6% for dyspepsia and 6.6% for IBS. They also reported annual onset rates of 2.0% for heartburn several times a week or daily, 5.0% for heartburn once a month or more, and 3.9% for acid regurgitation once a month or more. In Sweden, Lööf et al calculated the annual incidence of reflux oesophagitis, using upper gastrointestinal endoscopy, to be 120 per 100,000 inhabitants in a primary healthcare population. However, this study probably underestimated the incidence of gastro-oesophageal reflux symptoms as it was a patient-based study on oesophagitis. In another Swedish population-based study, the reported values were lower than in most other studies, probably because the methodology excluded those with prior, now recurrent, symptoms. Table 3 shows the three month incidence of predominant reflux symptoms, dyspepsia, and IBS in this population.

SYMPTOMS

Symptom overlap

The symptoms of dyspepsia, often including reflux symptoms, and IBS overlap to a considerable extent, as shown in table 4. The symptom overlap and proportion of those with reflux symptoms reporting and not reporting dyspepsia (the latter defined as “predominant reflux symptoms”) in a Swedish population based study are shown in fig 1.

Symptom change over time

Although often chronic, the pain or discomfort suffered with dyspepsia is frequently intermittent, even during a period...
with marked symptoms. Most studies on symptom turnover however examined the changes over longer periods. Studies that have been undertaken on symptom change over time are shown in Table 5. Talley et al, for example, found that about 86% of individuals with frequent symptoms had the same symptom profile 12–20 months later. However, Palmer found that spontaneous recovery was three times more common than impairment among untreated GORD patients. Unfortunately, the results of a study by Schindlbeck et al were less encouraging—68% of patients (n=105) with GORD had the same or worse symptoms after three years. Furthermore, Ruth found that the majority of patients with GORD still reported symptoms in a 10 year follow up.

The results of a one year study of symptom turnover in a Swedish population (n=1059) are shown in Fig 2. At least half of the individuals had changed their main symptom profile over one year. However, when the same population was studied again after seven years (843 individuals (79.1%) of the original population responded to the questionnaire), a somewhat different pattern of symptom turnover was recorded. Those patients who were symptom free remained largely symptom free. Those with predominant reflux symptoms kept reporting reflux symptoms to a varying degree but they seldom changed their main symptom profile to dyspepsia or IBS. In contrast, the flux between the diagnoses of dyspepsia and IBS was substantial. There would therefore appear to be two distinct populations of patients reporting symptoms among those with functional gastrointestinal disorders: those with symptoms of dyspepsia or IBS, with common variation in between, and those with predominant reflux symptoms. This would also suggest different pathophysologies for the symptoms of these two populations.
PREDICTORS OF SYMPTOMS

When studying factors associated with the onset of a multifaceted disorder such as dyspepsia, methodological issues are crucial. Non-relevant covariation must be controlled using multivariate analysis.

Sociodemographic and environmental factors

In the Swedish study by Agréus et al, risk factors for developing functional gastrointestinal symptoms were studied among symptomatic individuals who had been symptom free one year previously. In a univariate analysis, family size, educational level, and being listed sick during the previous three months were positively associated and age was negatively associated with the risk of developing symptoms, while sex, previous abdominal surgery, hormone treatment (in females), and the use of intrauterine devices were unrelated to the risk. When the univariate significant factors (including age and sex) were included in a multivariate model, educational level (odds ratio (OR): both sexes) 1.2; 95% confidence interval (CI) 1.0–1.5) and being listed sick during the previous three months (OR (both sexes) 2.9; 95% CI 1.1–7.7) remained weak predictive factors. However, this study can be criticised because some of the potential risk factors were not assessed and could not therefore be introduced into the model.

In Denmark, Kay and Jørgensen studied the influence of sex, age, social class, psychiatric vulnerability, experience of problems, body mass index (BMI), smoking, alcohol intake, coffee and tea intake, and intake of hormones (among females), and found that after multivariate analysis only psychiatric vulnerability significantly increased the risk of females), and found that after multivariate analysis only psychiatric vulnerability significantly increased the risk of dyspepsia, while smoking and a high BMI decreased the risk.

In particular, the use of proton pump inhibitors has increased slightly from 6.6 to 6.8 defined daily doses (DDD)/1000 inhabitants. Whereas the use of H2 receptor antagonists has increased from 6.6 to 6.8 defined daily doses (DDD)/1000 inhabitants. Hopefully, this reflects a rational use of the drugs for GORD and for the eradication of Helicobacter pylori in patients with peptic ulcer disease, and not an overuse of empirical treatment by chance in functional dyspepsia.

In another Swedish study on a population based sample from 1988, 8.3% of individuals with dyspepsia and 6.9% of those with GORD were listed as sick (for any reason) in the previous three months compared with 1.8% of those free from functional abdominal disorders. Approximately 5% of those with dyspepsia or reflux had consulted a doctor in the previous three months, and 50% of those in the oldest age group (that is, "life prevalence") had ever done so concerning dyspepsia or GORD. The overall drug consumption was substantial—approximately one in four had used drugs for gastrointestinal disorders during the previous three months and another 7% had used drugs for other disorders.

Almost half (47%) of the cost was for drugs, and two thirds of these costs were for proton pump inhibitors (table 7). The comparative cost from 1991 for the same country was US$825 million (after adjusting for the consumer price index and currency rate changes), with 90% of the cost being for short term sick leave, and just 2% for drugs. It is obvious that impairment in sickness benefits in Sweden has substantially reduced the costs to society—the qualifying period before benefit has been reduced from none in 1991 to one day in 1997, and the proportion of income loss compensation for sick leave has been reduced from 90–100% in 1990 to approximately 75–85% in 1997. On the other hand, most of the increase in drug costs is caused by an increase in the use of proton pump inhibitors. Whereas the use of H2 receptor antagonists has increased slightly from 6.6 to 6.8 defined daily doses (DDD)/1000 inhabitants between 1991 and 1997, the use of proton pump inhibitors has increased from 2.4 to 14.9 DDD/1000 inhabitants. Hopefully, this reflects a rational use of the drugs for GORD and for the eradication of Helicobacter pylori in patients with peptic ulcer disease, and not an overuse of empirical treatment by chance in functional dyspepsia.

Table 6 Costs of dyspepsia and gastro-oesophageal reflux disease in Sweden in 1997 (Agréus L. Economic impact of dyspepsia. Presented at the satellite meeting New Approaches to the Management of Dyspeptic Symptoms, held at the XXXth Nordic Meeting of Gastroenterology, Uleåborg, Finland, 1998)

<table>
<thead>
<tr>
<th>Category</th>
<th>US$ (millions)</th>
<th>Percentage of cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visits to primary care physicians</td>
<td>44</td>
<td>12</td>
</tr>
<tr>
<td>Visits to specialists</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Inpatient care</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Investigations (upper gastrointestinal endoscopies)</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>Drugs</td>
<td>170</td>
<td>47</td>
</tr>
<tr>
<td>Sick leave</td>
<td>84</td>
<td>23</td>
</tr>
<tr>
<td>Sickness pension</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Time off work, etc.</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>360</td>
<td></td>
</tr>
</tbody>
</table>

Table 7 Drug sales (proportion of the cost per group) for dyspepsia, gastro-oesophageal reflux disease, and “gastritis” in Sweden in 1996; total cost US$170 million

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Percentage of cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antacids/alginites</td>
<td>6</td>
</tr>
<tr>
<td>H2 receptor antagonists</td>
<td>21</td>
</tr>
<tr>
<td>Proton pump inhibitors</td>
<td>67</td>
</tr>
<tr>
<td>Prokinetics</td>
<td>6</td>
</tr>
</tbody>
</table>
third with the worst rated symptoms, approximately 35% had used a gastrointestinal drug and 10% other drugs during the same time spans. A US study found the mean costs to a health maintenance organisation of “gastritis”, reflux disease, and peptic ulcer disease to be US$25 per person, or about one fifth of the costs of diabetes mellitus. The costs do not include the costs of sick leave or a sickness pension. The proportions were 22.6% for dyspepsia, 36.8% for peptic ulcer disease, and 40.6% for GORD. For those with dyspepsia, 6% of the costs were for inpatient care, 80% for outpatient care, and 14% for drugs. Values for peptic ulcer disease were 71%, 23%, and 6%, respectively, and for GORD 28%, 57%, and 15%. These values show a completely different pattern of cost distribution compared with the Swedish studies (Agréus L. Economic impact of dyspepsia. Presented at the satellite meeting New Approaches to the Management of Dyspeptic Symptoms, held at the XXXth Nordic Meeting of Gastroenterology, Uleåborg, Finland, 1998), indicating how important it is to consider the impact of different social and healthcare insurance systems, as well as other cultural influences when comparing costs for diseases.

CONCLUSION
Dyspepsia is a common, long term, fluctuating, symptom shifting, and expensive disorder.

Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The author of this paper has received sponsor- ship for travel and an honorarium from AstraZeneca.

REFERENCES
15. Talley NJ, Piper DW, the association between non-ulcer dyspepsia and irritable bowel syndrome in the Netherlands and Japan. Scand J Gastroenterol 1993;28:331–41.

55 Ruth M. Vad händer med esofagala symptom med tiden? (What happens with oesophageal symptoms over time?) Svenska Läkarsällsk Handl 1997;106:GA42.


